Anticonvulsant effect of equilibrative nucleoside transporters 1 inhibitor in a mouse model of Dravet syndrome

There are limited therapeutic options for patients with Dravet syndrome (DS). The equilibrative nucleoside transporters 1 (ENT1) mediate both the influx and efflux of adenosine across the cell membrane exerted beneficial effects in the treatment of epilepsy. This study aimed to evaluate the anticonvulsant effect of the ENT1 inhibitor in an animal model of DS (Scn1a(E1099X/+) mice). J7 (5 mg/kg) treatment was efficacious in elevating seizure threshold in Scn1a(E1099X/+) mice after hyperthermia exposure. Moreover, the J7 treatment significantly reduced the frequency of spontaneous excitatory post-synaptic currents (sEPSCs, similar to 35% reduction) without affecting the amplitude in dentate gyrus (DG) granule cells. Pretreatment with the adenosine A1 receptor (A1R) antagonist, DPCPX, abolished the J7 effects on sEPSCs. These observations suggest that the J7 shows an anticonvulsant effect in hyperthermia-induced seizures in Scn1a(E1099X/+) mice. This effect possibly acts on presynaptic A1R-mediated signaling modulation in granule cells.

Automated summary

The ENT1 inhibitor J7 has been found to have anticonvulsant effects in an animal model of Dravet syndrome, possibly by modulating the presynaptic A1R-mediated signaling in granule cells.